20 May 2013
Keywords: strong, vivo, data, ablynx, antiviral, nanobody, belgian
Article | 19 January 2009
Belgian drug discovery firm Ablynx says it has completed studies showing that antiviral antibodies derived from its Nanobodies platform give
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
19 January 2009
© 2013 thepharmaletter.com